INTRODUCTION
The concept of liquid biopsy has been introduced not only in research, but also in clinical practice to detect cancer-related gene
액체생검을 위한 세포유리 DNA 추출에 검사 전 변동요인이 미치는 영향
Effects of Pre-analytical Variables on Cell-free DNA Extraction for Liquid Biopsy ination by genomic DNA from cellular components in the specimen [12, 13] . In addition, as the amount of cfDNA present in the blood is very small, a large volume of sample (plasma) is required compared with that required for the extraction of genomic DNA [14] . Subsequent molecular diagnostic techniques after cfDNA extraction can be performed in clinical practice only if suf cient quantity and quality of cfDNA is available. Although quality management of cfDNA extraction is very important to obtain reliable liquid biopsy results, standardization of the cfDNA extraction process has not yet been achieved [15, 16] . Some previous studies have reported results for the evaluation of pre-analytical variables that may affect cfDNA extraction [17] [18] [19] [20] [21] , but there are still insufcient data on cfDNA extraction methods that can be applied to clinical laboratories as a routine practice.
In this study, we aimed to evaluate the pre-analytical factors affecting cfDNA extraction for liquid biopsy by comparing the type of specimen container and sample storage conditions.
MATERIALS AND METHODS

Study design and sample collection
The schematic ow of the study is summarized in Fig. 1 . To assess the effect of specimen containers and storage conditions, venous blood from 10 subjects ( ve healthy volunteers and ve lung cancer patients) was collected using two 6 mL K2-EDTA containers (BD Vacutainer, Franklin Lakes, NJ, USA) and one 10 mL CellFree DNA BCT container (Streck, La Vista, NE, USA). Blood collection using the BCT container was performed according to the instruction manual [22] . To minimize transportation time of samples, venous blood collection of all study participants was performed in the laboratory. Venous blood in K2-EDTA containers was immediately processed by two steps of centrifugation to separate the plasma, which was aliquoted into four microtubes and stored at 4˚C. The cfDNA was extracted from the stored EDTA plasma samples and the performance of cfDNA extraction was compared based on storage time (<1 hr or baseline, and 6, 24, and 48 hr) (Fig. 1A) . Venous blood drawn into the BCT container was stored at room temperature for up to 14 days. On days 1, 3, 7, and 14 after the blood draw, approximately 2.5 mL of blood was removed from the BCT container and plasma was separated by two steps of centrifugation. Subsequently, cfDNA was extracted from the plasma and the performance of cfDNA extraction was compared up to 14 days (<1 day or baseline, and 3, 7, and 14) (Fig. 1A) .
To assess the effect of delayed centrifugation time for K2-EDTA samples, whole blood was collected in ve K2-EDTA containers from ve distinct healthy volunteers (Fig. 1B) . Blood in two containers was immediately centrifuged in two steps, aliquoted into four microtubes, and stored at 4˚C for 48 hr. The remaining three K2-EDTA containers were stored at 4˚C for 48 hr. The performance of cfDNA extraction was compared between plasma samples obtained by immediate centrifugation after blood draw and those with delayed centrifugation (6, 24 , and 48 hr) of refrigerated whole blood (Fig. 1B) . 
Plasma separation
Centrifugation for plasma separation was performed in two steps as described in the reagent package insert of the MagMAX Cell-Free DNA Isolation Kit (Thermo Fisher Scienti c, Waltham, MA, USA). First, whole blood samples were centrifuged at 2,000×g for 10 minutes at 4˚C. After the rst centrifugation, the plasma part of the upper layer was carefully removed, transferred to a new microtube, and centrifuged at 16,000×g for 10 minutes at 4˚C. After the second centrifugation, the upper plasma layer was carefully removed and transferred to a new microtube.
Extraction of cfDNA
The cfDNA was extracted in an automated manner using a MagMAX Cell-Free DNA Isolation Kit and the KingFisher Duo Prime Puri cation System (Thermo Fisher Scienti c). All procedures were carried out according to the manufacturer's instructions. When blood samples were collected from the BCT specimen, proteinase K treatment was performed after plasma separation. The input plasma volume was 1.0 mL and the cfDNA was eluted in 30 μL of the elution buffer provided by the manufacturer. The extracted cfDNA was transferred to a microtube and stored at lower than -70˚C.
Measurement of cfDNA concentration and fragment size
The Qubit dsDNA HS Assay Kit (Thermo Fisher Scienti c) and were used to evaluate the fragment size of nucleic acids. Venous whole blood (WB) was drawn from 10 subjects (healthy controls, N=5; lung cancer patients, N=5). The cell-free DNA (cfDNA) was extracted under different specimen storage conditions in K2-EDTA at 4°C and Cell-Free DNA BCT containers at room temperature (RT). (B) Venous blood was drawn from five healthy subjects in K2-EDTA containers, and the cfDNA was extracted under different centrifugation conditions. ve lung cancer patients are described in Table 2 . Fig. 2 . Comparison of cell-free DNA (cfDNA) concentrations according to specimen container in healthy controls and patients with lung cancer. The cfDNA concentration of patients with lung cancer was significantly higher than that of healthy controls. In the healthy control group, the mean concentration of cfDNA in the K2-EDTA container was significantly higher than that of the Cell-Free DNA BCT containers. (Fig. 3A) . In the evaluation of DNA fragment size, nucleic acids of approximately 150-200 bp were observed, and the size of cfDNA in EDTA plasma stored at 4˚C was not signi cantly different up to 48 hr for both groups ( Fig. 3B and 3C ).
EGFR mutation analysis
Comparison of cfDNA according to storage conditions in BCT containers
When BCT containers were stored at room temperature, there was a signi cant difference in cfDNA concentration over time in both healthy controls (P = 0.0097 by Friedman test) and lung cancer patients (P = 0.0015 by Friedman test). There was no signicant difference in both groups until day 7 compared to baseline.
On day 14, however, the amount of cfDNA signi cantly increased compared to baseline in both healthy controls (P = 0.0253 by Friedman test) and patients with lung cancer (P = 0.0253 by Friedman test) (Fig. 3D) .
In both groups, nucleic acids of about 150-200 bp were mainly observed. The fragment size of cfDNA in BCT samples did not change signi cantly up to day 7. On day 14, however, an increase in nucleic acid size to greater than 1,000 bp, suggesting genomic DNA, was observed in both healthy controls and patients with lung cancer (Fig. 3E and 3F ).
Effect of delayed centrifugation in K2-EDTA containers
There was no signi cant difference in the extraction of cfDNA immediately after plasma separation when cfDNA was extracted after whole blood was refrigerated, and the total amount of cfDNA signi cantly increased with time (P = 0.0256 by one-way repeated ANOVA test). In addition, there was a signi cant difference in cfDNA concentration from the 24 hr storage sample (P = 0.0056 by paired t-test) depending on centrifugation delay (Fig. 4A) . The amount of cfDNA according to plasma separation conditions (immediate centrifugation vs. delayed centrifugation) for each of the ve healthy subjects is described in Table 3 . There was no signi cant difference in the fragment size of the nucleic acid until 48 hr for stored EDTA plasma (Fig. 4B) . However, for Abbreviations: BCT, cell-free DNA BCT container; SD, standard deviation. EDTA whole blood stored at 4˚C, an increase in the size of nucleic acids to 2,000 bp or greater was observed after 24 hr (Fig. 4C ).
EGFR gene mutation analysis
The EGFR test results with the semi-quantitative index (SQI) of the cfDNA specimens extracted from each patient according to the specimen container type and storage conditions are described in Recently, quality control material for cfDNA analysis has been reported [24] , and efforts to improve the quality of cfDNA-related tests are expected to continue.
Although there is no standardized operating procedure guideline for cfDNA extraction that can be used in clinical laboratories, it is widely accepted that blood samples are collected in a container containing EDTA anticoagulant, and the plasma can be separated by two steps of centrifugation under different conditions [12, [15] [16] [17] [18] [19] [20] [21] . To obtain optimal cfDNA for downstream analy- Although the type of specimen, the anticoagulant, and the centrifugation method for cfDNA extraction were consistent in previous studies [12, [15] [16] [17] [18] [19] [20] [21] , the safe time to delay centrifugation without genomic DNA contamination was reported to vary from 2 hr
[25] to 72 hr [19] at 4˚C (EDTA tubes) depending on the researcher.
In routine laboratory practice, one of the most important and practical factors is the duration a blood sample can be stored under certain conditions for cfDNA extraction. In our study, no signicant changes in cfDNA concentration was observed up to 48 hr for EDTA plasma and up to 6 hr for EDTA whole blood stored at 4˚C (Fig. 4A) . Large-sized nucleic acids were observed at 24 hr from baseline in the EDTA whole blood, and consequently there was a tendency for the cfDNA concentration to increase after 24 hr ( Fig.   4A and 4C ). Since the number of specimens evaluated by the authors was small (N = 5), we concluded that refrigeration of EDTA whole blood for up to 6 hr did not affect the cfDNA concentration. More samples and time points (e.g., 8 or 12 hr) are needed to con rm whether cfDNA was released from cellular components after 6 hr.
In our results, there was no signi cant difference in the amount and fragment size of cfDNA up to 48 hr when the plasma was immediately separated from the EDTA whole blood and stored at 4˚C (Fig. 3) . These ndings suggest that even after storage for 48 hr in refrigerated conditions, there was negligible genomic DNA contamination and cfDNA degradation for EDTA plasma. This was observed in both healthy controls and patients with lung cancer, and might be because the early stage two-step centrifugation process minimized genomic DNA contamination by removing as much of the cellular components as possible. In addition, in all three patients with lung cancer with EGFR gene mutations, the same mutation present at baseline was detected in EDTA plasma samples stored for 48 hr, and although statistical analysis was not possible due to the small number of sample, the SQI values of EGFR mutations were similar up to 48 hr. These results suggest that storage of immediately separated EDTA plasma for 48 hr probably does not affect the results of subsequent real-time PCRbased molecular analyses. In the present study, the exon 19 EGFR mutation was not detected in a EDTA plasma sample stored at 4˚C for 6 hr, which might be the result of a random error or lack of a duplicate or triplicate test.
Ideally, plasma should be separated as soon as possible from the drawn blood to obtain optimal cfDNA for downstream molecular analysis; however, this may be limited in some clinical laboratories depending on the available labor, facilities, and equipment. Therefore, on a practical level, if the EDTA plasma is immediately separated and stored at 4˚C, it may be possible to secure approximately 48 hr of time compared with storing EDTA whole blood at 4˚C for cfDNA analysis. However, further evaluation is necessary to determine whether ctDNA from stored EDTA plasma is preserved compared to the baseline. Although the half-life of ctDNA is unclear [26] , theoretically if the sample storage time is prolonged, the ctDNA will be gradually degraded and this might affect the nal results of the cfDNA analysis (e.g., EGFR gene mutation) due to the detection limit of the molecular test.
The BCT containers containing the K3-EDTA anticoagulant and cell preservative, and cfDNA can be stored on BCT at room temperature for up to 14 days [22] . Previous studies have reported the performance of BCT containers for cfDNA extraction, but the samples were usually evaluated after less than 5 days at room temperature [17, 19, 21] . We evaluated the cfDNA extraction per-www.labmedonline.org 55 formance using BCT stored at room temperature for up to 14 days. Our results showed no signi cant difference in cfDNA concentration using the BCT containers until day 7 between samples from healthy subjects and patients with cancer. On day 14, the total amount of cfDNA was increased, and larger nucleic acids were observed compared to baseline (Fig. 3) . BCT containers stabilize cfDNA and cellular genomic DNA for 14 days, whereas epithelial cells (tumor cells) are stable only up to 7 days [22] . Therefore, after 7 days, nucleic acid released from epithelial cells rather than white blood cells may cause an increase in cfDNA concentration. In this study, the EGFR gene mutation was con rmed in samples stored in BCT containers for up to 14 days in all three patients with lung cancer and con rmed mutations. In addition, the SQI values of EGFR mutations were similar up to 14 days. These results suggest that the BCT container could be safely used to store cfDNA for 14 days. However, on day 14, a decrease in the relative concentration of ctDNA was expected due to an increase in the total cfDNA concentration. Therefore, storage in the BCT container for up to 14 days may affect EGFR gene testing, and further studies with more samples are needed.
There were some limitations in this study. First, the number of specimens evaluated was small, and it is dif cult to generalize the results of the authors. Second, only automated cfDNA extraction using the MagMAX Cell-Free DNA Isolation Kit was evaluated, and various other methods were not studied. Third, we conrmed EGFR mutations according to specimen containers and storage conditions; however, we did not apply a quantitative approach for EGFR mutations in patients with lung cancer.
In summary, cfDNA isolated using the MagMAX Cell-Free DNA Isolation Kit could be stable for 6 hr for EDTA whole blood at 4˚C, for 48 hr for immediately centrifuged EDTA plasma at 4˚C, and for 
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